Biotech Stocks in the News – DNDN, GILD, MNKD, ONCY
Houston, TX – February 11 , 2013 — (Net PR News) – AnotherWinningTrade.com, the leader for breaking information and up-to-date market activities on Wall Street, locates high-growth equity opportunities. To receive our FREE, comprehensive newsletter, visit AnotherWinningTrade.com.
During the Previous Trading Session, Biotech Stocks Moving Upward – NASDAQ:DNDN, NASDAQ:GILD, NASDAQ:MNKD, NASDAQ:ONCY
Dendreon Corporation (NASDAQ:DNDN) revealed that, to review its financial results for the quarter and full year 2012, on Monday, February 25, 2013, at 9:00 a.m. ET / 6:00 a.m. PT, the company’s management will present a conference call.
Dendreon Corporation percentage change advanced 6.80% to close at $6.91 with the total traded volume of 13.42 million shares, as compared to average volume of 7.50 million shares.
Is DNDN A Solid Investment At These Levels? Find Out Exactly Where DNDN Is Headed With This TREND ANALYSIS REPORT
The Company’s lowest price during last trade was $6.50 while its highest price was $7.22 for the day. DNDN’s total market capitalization is $1.07 billion along with 154.32 million shares outstanding. Its beta value stands at 3.91 points and its earning per share remained $-2.31.
Gilead Sciences, Inc. (NASDAQ:GILD) reported an upsurge of 1.34% after opening at the price of $40.32. Its closing price for the day was $40.90.
GILD’s total trading volume for the day was 8.97 million shares, versus its average volume of 9.00 million shares. The Company’s current market capitalization stands at $61.98 billion along with 1.52 billion shares.
Get A Free Report And Detailed Analysis On GILD CLICK HERE To Read
Gilead Sciences Company’s earnings per share is $1.63 while its beta value stands at 0.46 times. If we look at the previous 5 day’s performance of the stock, it remained increasing with the gain of 0.84%, in its last one month’s trade it surged 5.68%.
MannKind Corporation (NASDAQ:MNKD) unveiled that, on Monday, February 11, 2013, it will release its financial results for the 2012 fourth quarter and full year. On the same day, at 5:00 PM (Eastern Time), the management of the company will present a conference call to discuss its financial results for the fourth quarter and fiscal year and other developments of the company.
MannKind Corporation percentage change advanced 10.13% to close at $2.61 with the total traded volume of 7.40 million shares, as compared to average volume of 3.21 million shares.
How Should Investors React To MNKD Now? Find Out In This TREND ANALYSIS REPORT
Its market capitalization is $641.48 million and EPS was $-1.02. MNKD’s shares were trading within the range of $2.39-$2.63 while its opening price was $2.40. If we look at its previous three months trade, it surged 35.23% while in last the 5 day’s it remained up 8.98%.
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) reported the increase of 21.85% and closed at $4.35 with the total traded volume of 8.89 million shares. The stock’s opening price was $4.65. The company has total a of 76.69 million outstanding shares and its total market capitalization is $333.61 million.
How Should Investors Trade ONCY Now? Don’t Trade ONCY Until You Read This TREND ANALYSIS REPORT
The 52-week price range of the stock remained $1.60 – $5.29, while during last trade its minimum price was $4.23 and it gained its highest price of $4.93. The Company’s last 5 days shows an uptrend of 12.4%.
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.